EQS-News: Marinomed Biotech AG / Key word(s): Quarterly / Interim
Statement
Marinomed Biotech AG announces results for the first quarter of 2025
08.05.2025 / 09:20 CET/CEST
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
Marinomed Biotech AG announces results for the first quarter of 2025
• Revenues for the first quarter of 2025 increased to EUR 6.5 million
compared to EUR 0.7 million in Q1 2024 -steep increase of operating
result to EUR 22.2 million compared to EUR -1.9 million Q1 2024
• Cash and cash equivalents increased to EUR 4.5 million compared to EUR
1.7 million in Q1 2024
• Investigations concerning the cyber fraud are ongoing; Despite the
case the company is within its plans concerning liquidity
Korneuburg, Austria, May 8, 2025 - Marinomed Biotech AG (VSE:MARI)
announces revenues of EUR 6.5 million recorded in the first quarter of
2025 primarily due to the first payment of EUR 5.0 million for the sale of
the Carragelose business unit to Unither Pharmaceuticals. Also, the
operating result was strongly positive with EUR 22.2 million in Q1. These
numbers include a restructuring gain of EUR 18.9 million. The cash and
cash equivalents increased to EUR million 4.5 compared to EUR 1.7 million
in Q1 2024 despite the cyber fraud case. The payment of the first quota to
Marinomed´s creditors are reflected, excluding a EUR 1,18 million quota
payment to the EIB, which was served in April.
“In the first quarter of 2025, the positive outcome of the restructuring
procedure resulted in a highly positive result. Marinomed has completed
the sale of the Carragelose business and secured the first payment in the
size of EUR million 5.0. After the successful restructuring and divestment
of the Carragelose business we focus on maximizing the earnout from the
sale of the business and the commercialization of our assets derived from
the Marinosolv platform”, Andreas Grassauer, CEO of Marinomed, mentions.
“, the recent launch of the Carragelose eyedrops in Austria is supportive
for the plans of receiving the planned earnouts for the Carragelose
business in time. Carragelose eyedrops are currently featured at ARVO
2025, the Annual Meeting of the Association for Research in Vision and
Ophthalmology in Salt Lake City, Utah USA.”
“The positive result, the improved cash position and the restructured
balance sheet reflect the transformation of Marinomed after the
restructuring. Despite the obstacles from the cyberfraud case the company
is within its plans concerning liquidity.”, Gabriele Ram, CFO of
Marinomed, adds. “We are continuing the fruitful work with Unither not
only for a successful business transition, but also for the growth of the
business. Therefore, we are confident that the earnout payments of up to
EUR million 15 can be realized in the planned time. Beyond that we are
working hard on our goals of commercializing the key assets of the
Marinosolv platform and the growths of our Solv4U business.”
Selected financial figures for Q1 2025
All amounts in kEUR Q1 2025 Q1 2024
Revenues 6.531,2 737,5
Operating result (EBIT) 22.222,9 -1.861,7
Result for the period 22.122,1 -2.176,8
Cash flow utilized by operating activities 2.864,0 -1.084,4
31.03.2025 31.03.2024
Cash and cash equivalents 4.573,4 1.706,4
Current financial liabilities 2.369,5 28.230,7
Non-current financial liabilities 8.932,3 0
Capital and reserves -4.036,5 -26.158,6
Balance sheet total 10.428,9 8,183,3
About Marinomed Biotech AG
Marinomed Biotech AG is an Austrian, science-based biotech company with a
growing development pipeline. The Company develops innovative
patent-protected products based on the Marinosolv® platform. The
Marinosolv® technology improves the solubility and bioavailability of
hardly soluble compounds and is used to develop new therapeutics for
autoreactive immune disorders. The Company is headquartered in Korneuburg,
Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For
further information, please visit: https://www.marinomed.com.
For further inquiries contact:
Marinomed Biotech AG
PR: Luca Horinek
IR.: Tobias Meister
T: +43 2262 90300 158
E-Mail: (1)pr@marinomed.com
E-Mail: (2)ir@marinomed.com
Disclaimer
This press release contains forward-looking statements, which are based on
current views, expectations and projections of the management of Marinomed
Biotech AG about future events. These forward-looking statements are
subject to risks, uncertainties and assumptions that could cause actual
results, performance or events to differ materially from those described
in, or expressed or implied by, such statements. The current views,
expectations and projections of the management of Marinomed Biotech AG may
be identified by the context of such statements or words such as
“anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
and “target”. Forward-looking statements are only valid as of the date
they are made and Marinomed Biotech AG does not assume any obligation to
update, review or revise any forward-looking statements contained in this
press release whether as a result of new information, future developments
or otherwise.
══════════════════════════════════════════════════════════════════════════
08.05.2025 CET/CEST This Corporate News was distributed by EQS Group.
www.eqs.com
══════════════════════════════════════════════════════════════════════════
Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 2132742
End of News EQS News Service
2132742 08.05.2025 CET/CEST
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2132742&application_name=news&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf
References
Visible links
1. mailto:pr@marinomed.com
2. mailto:ir@marinomed.com
OTS original text press release with the exclusive in terms of content of the sender – www.ots.at |